Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) Wit
This study aims to compare modified CAPD (M-CAPD) and conventional CAPD (C-CAPD) in terms of delivering high-quality, goal-directed PD as well as avoiding resource wastage in prevalent ESKD patients aged 2 to ≤18 years using a randomized cross-over study design for one year. This study hypothesizes that M-CAPD will hav
| Condition(s) | Children on Chronic Peritoneal Dialysis |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study aims to compare modified CAPD (M-CAPD) and conventional CAPD (C-CAPD) in terms of delivering high-quality, goal-directed PD as well as avoiding resource wastage in prevalent ESKD patients aged 2 to ≤18 years using a randomized cross-over study design for one year. This study hypothesizes that M-CAPD will have better ultrafiltration and solute clearance than C-CAPD. Specific objectives 1. To determine the ultrafiltration efficiency by measuring the following: 1. Clinical parameters: blood pressure, weight, evidence of fluid overload by the presence of edema, abnormal heart sounds (S3 gallop), lung crackles or rales, increased heart rate (tachycardia), rapid breathing (tachypnea), 2. Change in the number of blood pressure medications before and after the intervention, 3. Absolute |
| Who can participate | Inclusion Criteria: * CKD 5D who have been on peritoneal dialysis for at least three months. Exclusion Criteria: 1. Patients with BSA of ≥1.5 m2, 2. Evidence of mechanical causes of low ultrafiltration capacity (hernia, peri-catheter, or genital leaks, pleuroperitoneal communication), 3. Peritoneal membrane failure (encapsulating peritoneal sclerosis), 4. Recent episode of peritonitis (within two months) 5. Those who have been on hemodialysis before switching to PD in the last three weeks. |
| Ages | 2 Years to 18 Years |
| Sex | All |
| Lead sponsor | National University Health System, Singapore |
| Locations | Manila, Ermita, Philippines |
| Start date | 2024-11-18 |
| NCT ID | NCT07134595 |
| Official listing | https://clinicaltrials.gov/study/NCT07134595 |